Norpandamarilactonine A



Compound IDCDAMM00306
Common nameNorpandamarilactonine A
IUPAC name4-methyl-2-pyrrolidin-2-yl-2H-furan-5-one
Molecular formulaC9H13NO2

Experimental data

Retention time9.057
Adduct[M+H]+
Actual mz168.102
Theoretical mz168.102
Error2.34
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score7.96

Identifiers and class information

Inchi keyLJJVKZSKPLBBSU-UHFFFAOYNA-N
SmilesO=C1OC(C=C1C)C2NCCC2
SuperclassOrganoheterocyclic compounds
ClassDihydrofurans

Plant source

  • Pedalium murex L.

    • Pharmacokinetic properties

    Number of descriptor values(#stars)0
    Number of non-conjugated amine groups (#amine)1
    Number of amidine and guanidine groups (#amidine)0
    Number of carboxylic acid groups (#acid)0
    Number of non-conjugated amide groups (#amide)0
    Number of rotatable bonds (#rotor)0
    Number of reactive functional groups (#rtvFG)0
    Predicted central nervous system activity (CNS)1
    Molecular weight (mol_MW)167.207
    Computed dipole moment(dipole)6.556
    Total solvent accessible surface area (SASA)391.402
    Hydrophobic component of SASA (FOSA)273.058
    Hydrophilic component of SASA (FISA)88.138
    Pie component of the SASA (PISA)30.206
    Weakly polar component of the SASA (WPSA)0
    Total solvent accesible volume (volume)627.078
    Number of hydrogen bond donors (donorHB)1
    Number of hydrogen bond acceptors (accptHB)4.5
    Free energy of solvation of dipole (dip^2/V)0.0685399
    Index of cohesive interaction in solids (ACxDN^.5/SA)0.0114971
    Globularity descriptor (glob)0.905225
    Predicted polarizability in cubic angstroms (QPpolrz)19.23
    Predicted hexadecane/gas partition coefficient (QPlogPC16)5.164
    Predicted octanol/gas partition coefficient (QPlogPoct)10.44
    Predicted water/gas partition coefficient (QPlogPw)7.363
    Predicted octanol/water partition coefficient (QPlogPo/w)0.303
    Predicted aqueous solubility (QPlogS)-0.806
    Conformation-independent predicted aqueous solubility (CIQPlogS)-0.218
    Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-3.936
    Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)360.572
    Predicted brain/blood partition coefficient (QPlogBB)0.245
    Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)181.715
    Predicted skin permeability, log Kp (QPlogKp)-5.1
    PM3 calculated ionization potential (IP(ev))9.548
    PM3 calculated electron affinity (EA(eV))0.431
    Number of likely metabolic reactions (#metab)2
    Prediction of binding to human serum albumin (QPlogKhsa)-0.451
    Predicted qualitative human oral absorption (HumanOralAbsorption)2
    Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)74.486
    Solvent-accessible surface area of fluorine atoms (SAFluorine)0
    Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
    Van der Waals surface area (PSA)56.779
    Number of nitrogen and oxygen atoms (#NandO)3
    Number of violations of Lipinski’s rule of five (RuleOfFive)0
    Number of violations of Jorgensen’s rule of three (RuleOfThree)0

    Compound-target network

    Cytoscape Graph

    Protein targets associated with phytocompound

    Uniprot ID Gene name Target name TTD_ID Prediction source
    P43681CHRNA4Neuronal acetylcholine receptor; alpha4/beta2T70967SwissTargetPrediction
    Q9Y5N1HRH3Histamine H3 receptorT64765SwissTargetPrediction
    P08173CHRM4Muscarinic acetylcholine receptor M4T20709SwissTargetPrediction
    P11229CHRM1Muscarinic acetylcholine receptor M1T28893SwissTargetPrediction
    P20309CHRM3Muscarinic acetylcholine receptor M3T67684SwissTargetPrediction
    P36544CHRNA7Neuronal acetylcholine receptor protein alpha-7 subunitT34429SwissTargetPrediction
    Q16853AOC3Amine oxidase, copper containingT69619SwissTargetPrediction
    P27487DPP4Dipeptidyl peptidase IVT31391SwissTargetPrediction
    O60341KDM1ALysine-specific histone demethylase 1T16739SwissTargetPrediction
    P28223HTR2ASerotonin 2a (5-HT2a) receptorT32060SwissTargetPrediction
    P28335HTR2CSerotonin 2c (5-HT2c) receptorT83813SwissTargetPrediction
    P41595HTR2BSerotonin 2b (5-HT2b) receptorT31204SwissTargetPrediction
    P32297CHRNA3Neuronal acetylcholine receptor; alpha3/beta4T74166SwissTargetPrediction
    P28222HTR1BSerotonin 1b (5-HT1b) receptorT07806SwissTargetPrediction
    P28221HTR1DSerotonin 1d (5-HT1d) receptorT11072SwissTargetPrediction
    P08908HTR1ASerotonin 1a (5-HT1a) receptorT78709SwissTargetPrediction
    P34969HTR7Serotonin 7 (5-HT7) receptorT79062SwissTargetPrediction
    P11086PNMTPhenylethanolamine N-methyltransferaseT56496SwissTargetPrediction
    Q9H3N8HRH4Histamine H4 receptorT26500SwissTargetPrediction
    P23975SLC6A2Norepinephrine transporterT21945SwissTargetPrediction
    P08172CHRM2Muscarinic acetylcholine receptor M2T46185SwissTargetPrediction
    Q6V1X1DPP8Dipeptidyl peptidase VIIIT15855SwissTargetPrediction
    Q86TI2DPP9Dipeptidyl peptidase IXT66252SwissTargetPrediction
    P19801AOC1Diamine oxidaseT77546SwissTargetPrediction

    Target associated diseases

    TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
    T70967DI0029Aneurysm/dissection[ICD-11: BD50]P43681CHRNA4
    T70967DI0191Hypertensive crisis[ICD-11: BA03]P43681CHRNA4
    T70967DI0196Hypotension[ICD-11: BA20-BA21]P43681CHRNA4
    T64765DI0392Somnolence[ICD-11: MG42]Q9Y5N1HRH3
    T20709DI0037Asthma[ICD-11: CA23]P08173CHRM4
    T20709DI0141Eye anterior segment structural developmental anomaly[ICD-11: LA11]P08173CHRM4
    T20709DI0166Glaucoma[ICD-11: 9C61]P08173CHRM4
    T20709DI0293Nausea/vomiting[ICD-11: MD90]P08173CHRM4
    T20709DI0362Respiratory system disease[ICD-11: CB40-CB7Z]P08173CHRM4
    T28893DI0001Abdominal pelvic pain[ICD-11: MD81]P11229CHRM1
    T28893DI0086Chronic obstructive pulmonary disease[ICD-11: CA22]P11229CHRM1
    T28893DI0101Corneal disease[ICD-11: 9A76-9A78]P11229CHRM1
    T28893DI0129Dystonic disorder[ICD-11: 8A02]P11229CHRM1
    T28893DI0154Functional bladder disorder[ICD-11: GC50]P11229CHRM1
    T28893DI0157Gastric ulcer[ICD-11: DA60]P11229CHRM1
    T28893DI0166Glaucoma[ICD-11: 9C61]P11229CHRM1
    T28893DI0186Hyperhidrosis[ICD-11: EE00]P11229CHRM1
    T28893DI0218Irritable bowel syndrome[ICD-11: DD91]P11229CHRM1
    T28893DI0331Parkinsonism[ICD-11: 8A00]P11229CHRM1
    T28893DI0333Peptic ulcer[ICD-11: DA61]P11229CHRM1
    T28893DI0371Sebaceous gland disorder[ICD-11: ED91]P11229CHRM1
    T67684DI0037Asthma[ICD-11: CA23]P20309CHRM3
    T67684DI0086Chronic obstructive pulmonary disease[ICD-11: CA22]P20309CHRM3
    T67684DI0154Functional bladder disorder[ICD-11: GC50]P20309CHRM3
    T67684DI0166Glaucoma[ICD-11: 9C61]P20309CHRM3
    T67684DI0293Nausea/vomiting[ICD-11: MD90]P20309CHRM3
    T67684DI0333Peptic ulcer[ICD-11: DA61]P20309CHRM3
    T67684DI0362Respiratory system disease[ICD-11: CB40-CB7Z]P20309CHRM3
    T67684DI0371Sebaceous gland disorder[ICD-11: ED91]P20309CHRM3
    T67684DI0382Sjogren syndrome[ICD-11: 4A43]P20309CHRM3
    T67684DI0411Tonus and reflex abnormality[ICD-11: MB47]P20309CHRM3
    T34429DI0101Corneal disease[ICD-11: 9A76-9A78]P36544CHRNA7
    T34429DI0370Schizophrenia[ICD-11: 6A20]P36544CHRNA7
    T69619DI0190Hypertension[ICD-11: BA00-BA04]Q16853AOC3
    T31391DI0009Acute diabete complication[ICD-11: 5A2Y]P27487DPP4
    T31391DI0417Type 2 diabetes mellitus[ICD-11: 5A11]P27487DPP4
    T16739DI0012Acute myeloid leukaemia[ICD-11: 2A60]O60341KDM1A
    T16739DI0025Alzheimer disease[ICD-11: 8A20]O60341KDM1A
    T16739DI0138Ewing sarcoma[ICD-11: 2B52]O60341KDM1A
    T16739DI0238Lung cancer[ICD-11: 2C25]O60341KDM1A
    T16739DI0241Lymphoma[ICD-11: 2A80-2A86]O60341KDM1A
    T16739DI0245Malignant haematopoietic neoplasm[ICD-11: 2B33]O60341KDM1A
    T16739DI0284Myelodysplastic syndrome[ICD-11: 2A37]O60341KDM1A
    T16739DI0286Myeloproliferative neoplasm[ICD-11: 2A20]O60341KDM1A
    T16739DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]O60341KDM1A
    T32060DI0009Acute diabete complication[ICD-11: 5A2Y]P28223HTR2A
    T32060DI0033Anxiety disorder[ICD-11: 6B00-6B0Z]P28223HTR2A
    T32060DI0073Cerebral ischaemia[ICD-11: 8B1Z]P28223HTR2A
    T32060DI0270Mood disorder[ICD-11: 6A60-6E23]P28223HTR2A
    T32060DI0331Parkinsonism[ICD-11: 8A00]P28223HTR2A
    T32060DI0337Pituitary gland disorder[ICD-11: 5A60-5A61]P28223HTR2A
    T32060DI0370Schizophrenia[ICD-11: 6A20]P28223HTR2A
    T83813DI0117Depression[ICD-11: 6A70-6A7Z]P28335HTR2C
    T83813DI0264Migraine[ICD-11: 8A80]P28335HTR2C
    T83813DI0308Obesity[ICD-11: 5B80-5B81]P28335HTR2C
    T83813DI0324Pain[ICD-11: MG30-MG3Z]P28335HTR2C
    T83813DI0337Pituitary gland disorder[ICD-11: 5A60-5A61]P28335HTR2C
    T31204DI0040Attention deficit hyperactivity disorder[ICD-11: 6A05]P41595HTR2B
    T31204DI0117Depression[ICD-11: 6A70-6A7Z]P41595HTR2B
    T31204DI0337Pituitary gland disorder[ICD-11: 5A60-5A61]P41595HTR2B
    T31204DI0354Psychotic disorder[ICD-11: 6A20-6A25]P41595HTR2B
    T74166DI0105Cough[ICD-11: MD12]P32297CHRNA3
    T07806DI0264Migraine[ICD-11: 8A80]P28222HTR1B
    T07806DI0337Pituitary gland disorder[ICD-11: 5A60-5A61]P28222HTR1B
    T07806DI0354Psychotic disorder[ICD-11: 6A20-6A25]P28222HTR1B
    T07806DI0370Schizophrenia[ICD-11: 6A20]P28222HTR1B
    T11072DI0264Migraine[ICD-11: 8A80]P28221HTR1D
    T11072DI0337Pituitary gland disorder[ICD-11: 5A60-5A61]P28221HTR1D
    T78709DI0033Anxiety disorder[ICD-11: 6B00-6B0Z]P08908HTR1A
    T78709DI0117Depression[ICD-11: 6A70-6A7Z]P08908HTR1A
    T78709DI0190Hypertension[ICD-11: BA00-BA04]P08908HTR1A
    T78709DI0264Migraine[ICD-11: 8A80]P08908HTR1A
    T78709DI0270Mood disorder[ICD-11: 6A60-6E23]P08908HTR1A
    T79062DI0025Alzheimer disease[ICD-11: 8A20]P34969HTR7
    T79062DI0040Attention deficit hyperactivity disorder[ICD-11: 6A05]P34969HTR7
    T79062DI0051Bipolar disorder[ICD-11: 6A60]P34969HTR7
    T79062DI0117Depression[ICD-11: 6A70-6A7Z]P34969HTR7
    T79062DI0265Mild neurocognitive disorder[ICD-11: 6D71]P34969HTR7
    T79062DI0331Parkinsonism[ICD-11: 8A00]P34969HTR7
    T79062DI0370Schizophrenia[ICD-11: 6A20]P34969HTR7
    T26500DI0037Asthma[ICD-11: CA23]Q9H3N8HRH4
    T26500DI0039Atopic eczema[ICD-11: EA80]Q9H3N8HRH4
    T26500DI0351Psoriasis[ICD-11: EA90]Q9H3N8HRH4
    T26500DI0366Rheumatoid arthritis[ICD-11: FA20]Q9H3N8HRH4
    T26500DI0432Vasomotor/allergic rhinitis[ICD-11: CA08]Q9H3N8HRH4
    T21945DI0013Acute pain[ICD-11: MG31]P23975SLC6A2
    T21945DI0040Attention deficit hyperactivity disorder[ICD-11: 6A05]P23975SLC6A2
    T21945DI0087Chronic pain[ICD-11: MG30]P23975SLC6A2
    T21945DI0101Corneal disease[ICD-11: 9A76-9A78]P23975SLC6A2
    T21945DI0117Depression[ICD-11: 6A70-6A7Z]P23975SLC6A2
    T21945DI0166Glaucoma[ICD-11: 9C61]P23975SLC6A2
    T21945DI0264Migraine[ICD-11: 8A80]P23975SLC6A2
    T21945DI0301Nicotine use disorder[ICD-11: 6C4A]P23975SLC6A2
    T21945DI0308Obesity[ICD-11: 5B80-5B81]P23975SLC6A2
    T21945DI0324Pain[ICD-11: MG30-MG3Z]P23975SLC6A2
    T21945DI0395Stomach cancer[ICD-11: 2B72]P23975SLC6A2
    T46185DI0037Asthma[ICD-11: CA23]P08172CHRM2
    T46185DI0166Glaucoma[ICD-11: 9C61]P08172CHRM2
    T46185DI0278Muscle disorder[ICD-11: FB32-FB3Z]P08172CHRM2
    T46185DI0333Peptic ulcer[ICD-11: DA61]P08172CHRM2
    T46185DI0362Respiratory system disease[ICD-11: CB40-CB7Z]P08172CHRM2
    T46185DI0371Sebaceous gland disorder[ICD-11: ED91]P08172CHRM2
    T15855DI0300Neutropenia[ICD-11: 4B00]Q6V1X1DPP8
    T66252DI0300Neutropenia[ICD-11: 4B00]Q86TI2DPP9

    Copyright © 2025